Pancreatic Cancer Research

ResearcherUniversity of ToyamaActive in the last 2 years

Banri Ogino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2422-8961; OpenAlex author ID A5052409688. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2026: 6 papers

Papers 6

  1. Development of novel serum peptide biomarkers for screening pancreatic cancer. Co-author DOI 10.1007/s00535-025-02314-z↗
  2. Third-Line Treatment Timing After Second-Line Discontinuation in Advanced Pancreatic Cancer: A 30-Day Landmark Analysis. Co-author DOI 10.1007/s12029-026-01565-0↗
  3. Clinical trajectories from first-line chemotherapy to best supportive care in unresectable pancreatic cancer: a 10-year real-world retrospective study. Co-author DOI 10.1016/j.ctarc.2026.101409↗
  4. Chemotherapy for Unresectable Pancreatic Cancer Complicated by Disseminated Intravascular Coagulation: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000002707↗
  5. Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic… Co-author DOI 10.1177/10966218261457190↗
  6. Longitudinal Changes in Inflammatory and Nutritional Status Are Associated With Survival in Advanced Pancreatic Cancer. Co-author DOI 10.1177/10966218261500247↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobuhiko Hayashi · 6 shared papers, 2026 · strength 1.58
  2. Ichiro Yasuda · 6 shared papers, 2026 · strength 1.58
  3. Shinya Kajiura · 5 shared papers, 2026 · strength 1.33
  4. Kohei Nagata · 4 shared papers, 2026 · strength 1.07
  5. Kazuto Tajiri · 3 shared papers, 2026 · strength 0.81
  6. Ryuji Hayashi · 1 shared paper, 2026 · strength 0.26
  7. Tsutomu Fujii · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.